Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with multidrug resistant HIV-1: A phase 3, multicenter, expanded access study

By afschroeder • June 5, 2025

Emu B, Kumar PN, Mills A, Berhe M, Cash BR, Kuo KL, Anstett K. Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with multidrug resistant HIV-1: A phase 3, multicenter, expanded access study. J Acquir Immune Defic Syndr. 2025 Jun 4. doi: 10.1097/QAI.0000000000003699. Epub ahead of print. PMID: 40465394.

Tags: Humanized IgG4 monoclonal antibody, Ibalizumab, Infectious Diseases, Multidrug-resistant human immunodeficiency virus type 1, Optimized background regimen, Publications, Viral entry inhibitor

Maternal and neonatal outcomes after infection with monkeypox virus clade I during pregnancy in DR Congo: a pooled, prospective cohort study

Vakaniaki EH, Barhishindi I, Mubiala A, Malembaka EB, Braunack-Mayer L, Nganga B, Sabiti Nundu S, Brosius I, Bracke S, Bangwen E, De Vos E, Colebunders[...]

Timeliness of yellow fever specimen collection and transport in Ghana, 2018-2022

Judson SD, Schroeder L, Asiedu-Bekoe F, Laryea DO, Boateng G, Gudjinu H, Ossom R, Danquah JF, Dowdy DW, Kenu E. Timeliness of yellow fever specimen[...]

Global burden of lower respiratory infections and aetiologies, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023

GBD 2023 Lower Respiratory Infections and Antimicrobial Resistance Collaborators. Global burden of lower respiratory infections and aetiologies, 1990-2023: a systematic analysis for the Global Burden[...]